clinical trial · NCT04581629
Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1
Calcilytix Therapeutics, Inc., a BridgeBio company·phase2·completed·n = 13
Autosomal Dominant Hypocalcemia (ADH)Autosomal Dominant Hypocalcemia Type 1 (ADH1)Encaleret
brief summary
The primary purpose of this study is to evaluate the safety, tolerability and effectiveness of encaleret in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1).
started
Sep 20, 2020
primary completion
Sep 7, 2023
completion
Sep 7, 2023
last updated
Nov 19, 2024
official title
A Phase 2b, Open-label Dose-ranging Study Evaluating the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics, and Efficacy of CLTX-305 (Encaleret) in Autosomal Dominant Hypocalcemia (ADH) Type 1
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol